1 Result: CureVac
CureVac's Patent Litigation Moves to Virginia, Ambrx Biopharma Receives Overweight Rating, Legend Biotech Gets Price Target Boost
May 19th, 2023
CureVac N.V. (Nasdaq: CVAC) has made an important announcement regarding the ongoing patent litigation initiated by Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX). CureVac's motion to transfer the litigation from the federal district court of Massachuset. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
FTC Secures Fair Pricing Protections by Taking Action Against Major Wholesale T-Shirt Distributors
October 08th, 2026October 08th, 2026Treasury Announces Enforcement Penalty for Violation of Outbound Program
October 07th, 2026FAA Funds Drone Research to Support Safe Integration
October 05th, 2026
Member Login